Evidence map›Paper›PMID 42135634›Full record

ArticleGenes & nutrition2026

The relationship between elongation of very long-chain fatty acids (ELOVL) 2 polymorphism rs953413 and blood n-3 HUFA levels: a secondary analysis of EPA treatment in the seAFOod polyp prevention trial.

Ge Sun, John R Davies, Tracey Mell, Mark Harland, Rasha N M Saleh, Amanda D Race, Paul M Loadman, Anne Marie Minihane, Mark A Hull

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ge SunLeeds Institute of Medical Research, University of Leeds, Leeds, UK.
John R DaviesLeeds Institute of Medical Research, University of Leeds, Leeds, UK.
Tracey MellLeeds Institute of Medical Research, University of Leeds, Leeds, UK.
Mark HarlandLeeds Institute of Medical Research, University of Leeds, Leeds, UK.
Rasha N M SalehNutrition and Preventive Medicine, Norwich Medical School, University of East Anglia, Norwich, UK.
Amanda D RaceInstitute of Cancer Therapeutics, University of Bradford, Bradford, UK.
Paul M LoadmanInstitute of Cancer Therapeutics, University of Bradford, Bradford, UK.
Anne Marie MinihaneNutrition and Preventive Medicine, Norwich Medical School, University of East Anglia, Norwich, UK.
Mark A HullLeeds Institute of Medical Research, University of Leeds, Leeds, UK. M.A.Hull@leeds.ac.uk.

Funding

Efficacy and Mechanism Evaluation Programme NIHR128210
6 · The paper itself

Abstract

backgroundIndividuals receiving a standardised daily dose of 2000 mg of the n-3 highly unsaturated fatty acid (HUFA) eicosapentaenoic acid (EPA) for 12 months in the seAFOod polyp prevention trial demonstrated wide inter-individual variability in red blood cell (RBC) EPA levels (expressed as % of total measured fatty acids). Eicosapentaenoic acid can be converted to n-3 docosapentaenoic acid (n-3DPA) by the elongase elongation of very long-chain fatty acids (ELOVL) 2. We tested whether single nucleotide polymorphisms (SNPs) in ELOVL2 (rs3734398, rs2236212, rs953413, rs3798713, rs9393903) are associated with differential RBC EPA and n-3DPA levels in seAFOod trial participants at baseline and while receiving EPA supplementation.

resultsSix hundred and three seAFOod trial participants had ELOVL2 genotype and RBC n-3 HUFA data. All five ELOVL2 SNPs were in strong linkage disequilibrium (R

conclusionsA secondary analysis of the seAFOod trial found that minor (A allele) homozygotes for the ELOVL2 SNP rs953413 have a higher baseline RBC n-3DPA level than G allele carriers. However, rs953413 genotype did not significantly influence ΔEPA, Δn-3DPA, or ΔDHA levels during 6 or 12 months of high-dose EPA supplementation. Therefore, we do not provide evidence that genetic variation in ELOVL2 contributes to the inter-individual variability in the circulating EPA level associated with high-dose EPA supplementation.

Indexed as

Eicosapentaenoic acidElongaseOmega-3 polyunsaturated fatty acids

Identifiers

PMID42135634
PMCPMC13227881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.